CASE STUDY

High-frequency ventilation augments the effect of inhaled nitric oxide in persistent pulmonary hypertension of the newborn

T. Hoehn, M. Krause, R. Hentschel


ABSTRACT: Does inhaled nitric oxide (iNO) during high-frequency ventilation (HFV) lead to a more pronounced improvement in oxygenation than iNO during conventional ventilation?

We report two cases of newborn infants with profound hypoxaemia, who did not respond with an increase in arterial oxygenation following iNO therapy during conventional mechanical ventilation. The first infant was a term neonate with persistent pulmonary hypertension of the newborn (PPHN) following postnatal hypoxia, the second patient a premature infant of 29 weeks of gestation with PPHN secondary to lung hypoplasia and perinatal asphyxia. After the initial failure of iNO we switched both neonates to HFV without NO, which did not lead to a significant improvement of oxygenation in either case. Shortly after the initiation of HFV a second trial of iNO was started.

Both infants responded favourably to iNO with a marked and sustained increase in arterial oxygenation and absent right-to-left shunting via the ductus arteriosus and the foramen ovale.

We conclude that the favourable response to inhaled nitric oxide is dependent on the degree of lung expansion and is more readily achieved by the use of high-frequency ventilation than conventional ventilation.


High-frequency ventilation (HFV) is widely used for rescue treatment of hypoxaemic neonates and premature infants [1]. Although its role as a first-line mode of ventilation has not been established, it is often applied in newborns with respiratory failure, who cannot be successfully managed with conventional mechanical ventilation (CMV). The results of recent studies investigating the theoretically diminished baro- and volutrauma remain equivocal. Nonetheless there is evidence for a decreased secretion of inflammatory mediators [2] and a reduced amount of lung oedema [3] using high-frequency oscillatory ventilation (HFOV) with or without additional application of exogenous surfactant.

Inhaled nitric oxide (iNO) as a treatment for neonatal pulmonary hypertension has been in use for the past few years, both in premature infants and in term neonates [4–9]. It is worth noting that the first published application of iNO in a premature infant, and the subsequent improvement of oxygenation, occurred during HFOV [10]. Although still an experimental treatment, NO inhalation plays an important therapeutic role in severe hypoxaemia of the newborn due mainly to extrapolmonary shunting [11, 12].

Recently, a randomized, multicentre trial showed that the combination of iNO and HFOV was superior in term neonates, as compared to either treatment alone [13]. We report a similar experience in a full-term neonate, but also in a premature infant of 29 weeks of gestation.

Case 1

The term infant was delivered by caesarean section because of maternal hypertension. There was no maternal history of infection. The infant was male and had a birth weight of 3,810 g and Apgar 9,10,10 (1,5,10); he became symptomatic at the age of 15 min with intercostal retractions and grunting. At that stage, capillary blood gases were: pH 7.23, capillary carbon dioxide tension ($P_{c, CO_2}$) 8.0 kPa (60 mmHg), capillary oxygen tension ($P_{c, O_2}$) 4.0 kPa (30 mmHg) in combination with an increasing inspiratory oxygen fraction ($F_{I,O_2}$). At the age of 2 h the neonatal transport team was called, which arrived about 1 h later. The infant was intubated and ventilated because of persistent cyanosis, antibiotic treatment was started and he was transferred to our neonatal intensive care unit. Upon arrival, bovine surfactant (100 mg·kg$^{-1}$) was applied; in order to achieve adequate oxygenation, peak inspiratory pressures (PIPs) up to 4.6 kPa were required (positive end-expiratory pressure (PEEP) 0.5 kPa, rate 70 breaths·min$^{-1}$, inspiratory time 0.35 s, mean airway pressure (MAP) 1.8 kPa, $F_{I,O_2}$ 1.0). After approximately 6 h a sudden deterioration of oxygenation and arterial blood pressure occurred, caused by a pneumopericard, which was relieved by drainage. During this event, profound hypoxia occurred for about 15 min, the continuously recorded arterial oxygen saturation ($S_{a,O_2}$) (measured by pulsoximetry) was approximately 20%. Following drainage of the pneumopericard...
HFV AND iNO IN PPHN

and simultaneous bilateral pneumothoraces a gradual stabilization was achieved. Only then was right-to-left shunting via the ductus arteriosus and the foramen ovale was diagnosed by echocardiography and a trial of iNO was started. Since no improvement in arterial oxygenation occurred (figs. 1a and 2a), iNO was stopped and the mode of ventilation was switched to HFV (Babylog 8000; Draeger, Luebeck, Germany). Ventilator settings at that stage were: MAP 2.4 kPa, rate 8 Hz, amplitude 100%, FiO2 1.0. Again no increase in arterial oxygen tension (PaO2) was recorded, so a second trial of iNO was commenced, this time during HFV. Ventilator settings at that stage were: MAP 2.4 kPa, rate 8 Hz, amplitude 100%, FiO2 1.0. Again no increase in arterial oxygen tension (PaO2) was recorded, so a second trial of iNO was commenced, this time during HFV. Within a few minutes, oxygenation improved rapidly (figs. 1b and 2b), the oxygenation index decreased from 114 to 4 over a period of 3 h, and the alveolar-arterial pressure difference for oxygen (PA-aO2) decreased from 652 to 203. Right-to-left shunting was no longer present on echocardiography, the improved oxygenation was sustained and iNO was gradually weaned over a period of 4 days. The initial concentration of NO was 70 parts per million (ppm), which was rapidly weaned to levels below 20 ppm. Peak NO2 was recorded at 3.7 ppm and methaemoglobin was measured at a maximum of 1.7%. Continuous monitoring of iNO and NO2 were performed using an electrochemical device (Bieler and Lang, Achern, Germany). Cranial ultrasound revealed a left-sided middle cerebral artery infarction, which was compatible with the electroencephalogram (EEG) findings; clinically no neurological abnormalities were noted. The infant was extubated after 10 days of HFV; no supplemental oxygen was required thereafter. The diagnosis was persistent pulmonary hypertension of the newborn (PPHN) caused by profound hypoxaemia secondary to pneumopericard and bilateral pneumothoraces.

Case 2

The female premature infant, 29 weeks of gestation, had a birth weight of 1,060 g, Apgar 7,8,8 (1',3',5'). She suffered severe postnatal asphyxia at age 20 min following spontaneous vaginal delivery. Lung hypoplasia due to prematurely ruptured membranes with subsequent oligohydramnios was suspected prenatally on sonography. Ventilator settings at that stage were: PIP 3.0 kPa, PEEP 0.5 kPa, rate 60 breaths·min⁻¹, inspiratory time 0.3 s, MAP 1.1

![Fig. 1. Alveolar-arterial pressure difference for oxygen (PA-aO2) and NO concentration in a term infant (Case 1) during treatment with: a) conventional ventilation plus inhaled nitric oxide (iNO); and b) high frequency ventilation (HFV) plus iNO. ■ NO; ý PA-aO2. ppm: parts per million. 1 mmHg=0.133 kPa.](image1)

![Fig. 2. Arterial oxygen tension (PaO2) and arterial oxygen saturation (Sao2) in a term infant (Case 1) during treatment with: a) conventional ventilation plus iNO; and b) HFV plus iNO. ■ PaO2; ý Sao2. For definitions see legend to figure 1. 1 mmHg=0.133 kPa.](image2)
kPa and $F_{I,O_2}$ 1.0. Echocardiography revealed right-to-left shunting via the ductus arteriosus and the foramen ovale and, in addition, tricuspid valve incompetence with a pulmonary arterial pressure gradient of 40 mmHg was demonstrated. A subsequent trial of iNO did not lead to any improvement in terms of oxygenation, as monitored by $P_{a,O_2}$ and $S_{a,O_2}$ (figs. 3a and 4a). In order to treat persistent hypoxaemia, mechanical ventilation was switched to the high-frequency mode (Babylog 8000), which led only to a minor increase in $S_{a,O_2}$ (settings: MAP 1.2 kPa, rate 11 Hz, amplitude 100%, $F_{I,O_2}$ 1.0). Following initiation of HFV a second trial of iNO was started. Within several minutes a pronounced improvement of oxygenation occurred (figs. 3b and 4b), which was sustained and permitted gradual weaning from the ventilator. The initial iNO dose was 70 ppm and was then gradually reduced to a concentration below 10 ppm. NO and methaemoglobin were below 4.4 ppm and 1.6%, respectively. After only 1 h of iNO therapy $F_{I,O_2}$ was 0.21, the infant was extubated after 5 days of HFV and did not require supplemental oxygen during spontaneous breathing. The cranial ultrasound showed a normal anatomy with no evidence of intra-cranial haemorrhage, this was also the case during further follow-up.

The diagnosis was persistent pulmonary hypertension of the newborn (PPHN) due to profound hypoxaemia following postnatal asphyxia and lung hypoplasia.

Discussion

In the two neonates with hypoxaemia described above (one premature infant of 29 weeks of gestation, one term infant) we found that combined treatment with HFV and iNO resulted in superior improvement in oxygenation when compared to the remaining three ventilatory regimens.

In order to evaluate the influence of the mode of ventilation on arterial oxygenation we chose a sequential approach, applying four different modalities: 1) conventional ventilation; 2) conventional ventilation plus iNO; 3) HFV; and 4) HFV plus iNO.

Earlier studies comparing HFV and conventional ventilation without differentiating between high and low volume strategies failed to prove benefits from the use of HFV in terms of oxygenation [14, 15]. In contrast, recent studies have shown that HFV acutely improves oxygenation in preterm infants with respiratory failure [16–20]. This is in contrast to the present findings, in which there...
was no more than a marginal improvement in oxygenation following the initiation of HFV. It is noteworthy that this lack of improvement occurred despite the use of higher mean airway pressures during HFV. According to the clinical experience of a variety of investigators, following the change from conventional ventilation to HFV mean airway pressures 0.1–0.2 kPa higher than those used with CMV are required [21]. This was the case in the premature infant (CMV: MAP 1.1 kPa; HFV: MAP 1.2 kPa), but not in the term infant (CMV: MAP 1.8 kPa; HFV: MAP 2.4 kPa). The increase in MAP was justified on clinical grounds in order to ensure adequate oxygenation. Although the concomitant alveolar recruitment did not lead to a decrease of oxygenation parameters, we do believe that this was the reason for a favourable response to the second trial of iNO. The high-frequency ventilator used (Babylog 8000) is a flow interrupting device. The Babylog requires high inspiratory flow rates (up to 30 L min⁻¹) and oscillations are created by an expiratory valve.

Inhaled nitric oxide has been shown to be a very potent pulmonary vasodilator in the newborn infant. According to several publications this is not only the case in term infants [4, 5, 22], but also in premature neonates [7–9]. Although it still has to be regarded as an experimental treatment and a variety of potential side-effects have to be looked at, iNO has emerged as a very promising therapeutic approach in PPHN. The probability of a positive clinical response to iNO in terms of improved oxygenation depends basically upon the underlying disease [13]. In the past the attempt has been made to define NO-responders and nonresponders according to their degree of improvement of oxygenation parameters. This remains at least controversial since, according to several authors, patients may only respond favourably in the course of several attempts of iNO, which is in line with our own experience. Response or nonresponse might be directly related to the degree of lung expansion [23], which can be inconsistent during the course of the underlying disease. The clinical response to iNO might also depend on the choice of the ventilatory strategy, since the regional distribution of NO changes with different modes of ventilation (CMV/HFOV/high-frequency jet ventilation) [24].

Side-effects of NO seen in in vitro investigations include an inhibition of platelet aggregation and adhesion [25]. Although, theoretically of serious concern, particularly in preterm infants, impairment of platelet function does not appear to occur clinically during iNO therapy. This is consistent with the findings of the recently published North American multicentre studies [11, 12], including infants from 34 weeks onward as well as a series of premature infants treated with iNO [8–10]. The fact that gestational age and weight ruled out proceeding to extracorporeal membrane oxygenation (ECMO) in the 29 weeks infant, and the profound hypoxaemia, led to the decision to apply iNO, despite the theoretically increased risk of intraventricular haemorrhage.

The dosage regimen of iNO implied the initial use of concentrations in the upper range of those used clinically. This approach is derived from the three North American randomized trials of inhaled nitric oxide using concentrations up to 80 ppm (Boston Massachusetts General Hospital [11], Boston Children’s Hospital, Ohmeda (both unpublished)). Subsequently we aimed at a rapid reduction of iNO concentrations (figs. 1 and 3). Meanwhile, there is evidence that a favourable response to iNO can be achieved with starting doses of 20 ppm or less [5, 26].

Recently Kinsella et al. [27] found an improvement in oxygenation in an animal model (the newborn lamb) using the combination of iNO and HFOV as compared to iNO and conventional ventilation. Subsequently they demonstrated that the combination of iNO and HFOV was superior to either treatment alone in human neonates with severe PPHN, who were candidates for extracorporeal membrane oxygenation (ECMO) [13]. An animal model using dogs with oleic acid-induced lung injury showed that a recruitment of gas exchange units with continuous positive airway pressure (CPAP) was necessary in order to produce a beneficial effect of iNO on the ventilation-perfusion distribution and oxygenation [28, 29]. In patients with adult respiratory distress syndrome (ARDS), the factors determining NO-induced improvement in arterial oxygenation and pulmonary vascular effects have been shown to be PEEP-induced alveolar recruitment and the baseline level of pulmonary vascular resistance [30]. According to these findings, the beneficial effect of combining iNO and HFV might be solely related to the increased degree of alveolar recruitment during HFV. A more homogenous lung expansion during HFV would appear to overcome the problem of varying opening pressures required for different compartments of the lung. This not only explains an earlier reduction of FIO₂, in the HFOV group in the latest multicentre HFOV trial [31], but also leads to the expectation of a more uniform distribution and resorption of iNO.

In the two cases described above we found a clear benefit, in terms of improved oxygenation, from the combination of high-frequency ventilation and inhaled nitric oxide, which could not be achieved by conventional ventilation and inhaled nitric oxide. This was not only the case in the term infant, but also in a premature infant of 29 weeks of gestation. We conclude that in order to reach the maximum effect of inhaled nitric oxide, adequate lung expansion is required. This appears to be more readily achieved by the use of HFV. A randomized, controlled trial evaluating the effect of the mode of ventilation on the efficacy of inhaled nitric oxide is necessary before clinical conclusions can be drawn.

References
5. Kinsella JP, Neish SR, Shafler E, Abman SH. Low-dose